Weight Loss and Body Shape with Lipodystrophy in South Africa

Lipodystrophy is a group of disorders characterised by abnormal loss or redistribution of body fat — not from dieting, but from disease or medication. In South Africa, the most clinically significant form is HIV-associated lipodystrophy (also called antiretroviral therapy lipodystrophy or HAART-associated lipodystrophy syndrome — HALS), affecting a substantial proportion of people on long-term antiretroviral therapy (ART). South Africa has the world's largest HIV treatment programme — approximately 5.5 million people on ART by 2025 — making lipodystrophy a major public health nutrition issue in this country. Additionally, rare genetic forms (familial partial lipodystrophy and congenital generalised lipodystrophy) affect small numbers of South Africans but are severely metabolically disruptive. Lipodystrophy is not simply a cosmetic issue: it drives insulin resistance, hypertriglyceridaemia, liver disease (NAFLD/MASLD), and cardiovascular risk — all requiring targeted nutritional management.

Types of Lipodystrophy: South African Relevance

Type Cause Body Fat Pattern SA Prevalence
HIV/ART Lipoatrophy Older nucleoside reverse transcriptase inhibitors (NRTIs): stavudine (d4T), zidovudine (AZT) Fat loss from face, limbs, buttocks; hollow cheeks, visible veins on arms Common in patients on older regimens; less so on modern TDF/TAF-based regimens
HIV/ART Lipohypertrophy Protease inhibitors (older generation), immune reconstitution, HIV itself Central fat accumulation: visceral abdominal fat, dorsocervical fat pad ("buffalo hump"), breast enlargement Common in patients on longer-term ART; increasingly recognised
Mixed lipodystrophy (HALS) Combined peripheral fat loss + central fat gain Thin limbs + protruding abdomen; dramatic body shape distortion Most common pattern in SA patients on ART >5 years
Familial Partial Lipodystrophy (FPLD) LMNA, PPARG, or PLIN1 gene mutations Fat loss from limbs and trunk; excess fat accumulation in face and neck Rare; underdiagnosed; often misdiagnosed as type 2 diabetes or PCOS in women
Congenital Generalised Lipodystrophy (CGL) AGPAT2, BSCL2 gene mutations Near-complete absence of body fat from birth; muscular appearance; severe metabolic disease Very rare; presents in childhood; requires specialist centre management

The Metabolic Consequences of Lipodystrophy

Fat tissue is not merely storage — it is metabolically active endocrine tissue. When fat is lost from the periphery and redistributes to visceral stores (or is largely absent), the metabolic consequences are severe:

Pancreatitis risk: Triglycerides above 10 mmol/L carry significant acute pancreatitis risk. Above 20 mmol/L is a medical emergency requiring hospitalisation. If you have severe hypertriglyceridaemia, a very low fat diet (<15% of calories from fat) is not just helpful — it is urgent and potentially life-saving. This requires dietitian input immediately.

HIV/ART Lipodystrophy: Diet and Lifestyle Strategy

Step 1: Regimen Switch Discussion with Your HIV Clinician

The most effective intervention for ART-associated lipoatrophy is switching away from the causative drug. In South Africa, the public sector standard of care has largely shifted away from stavudine (d4T) and zidovudine (AZT) — which are most strongly associated with lipoatrophy — to tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)-based regimens. If you are still on an older regimen showing lipoatrophy, speak to your HIV clinician about regimen optimisation before focusing on diet. Diet alone cannot reverse ART-induced lipoatrophy.

Step 2: Metabolic Management Through Diet

Once the regimen is optimised (or while awaiting a switch), diet targets the metabolic consequences:

For High Triglycerides (Very Common in HALS)

Fibre upgrade: Replace refined pap with oat porridge at breakfast — one of the highest-impact single food changes for improving lipid profiles in South African HIV patients. Add a tablespoon of ground flaxseed for additional omega-3 and fibre benefit.

For Insulin Resistance and Central Fat

For Fatty Liver (NAFLD/MASLD)

Familial Partial Lipodystrophy (FPLD): Specific Dietary Approach

FPLD (most commonly Dunnigan type — LMNA gene mutation) has an extremely severe metabolic phenotype. Women with FPLD are frequently diagnosed in their 30s when diabetes and severe hypertriglyceridaemia become apparent — many are initially misdiagnosed with type 2 diabetes or PCOS.

Exercise: The Most Underused Tool in Lipodystrophy

Exercise is particularly effective in lipodystrophy — improving insulin sensitivity, reducing visceral fat, and improving cardiovascular risk profile:

Exercise Type Benefit Recommendation
Aerobic exercise (walking, cycling, swimming) Burns visceral fat; improves insulin sensitivity; lowers triglycerides 150 min/week minimum; 300 min/week for significant fat loss
Resistance training (weights, bodyweight) Preserves and builds muscle mass; improves peripheral fat redistribution aesthetically; raises metabolic rate 2–3 sessions/week; particularly important for HALS patients with peripheral muscle wasting
HIIT (high-intensity intervals) Very effective for visceral fat loss; time-efficient Only if cardiac status cleared; not for patients with severe hypertriglyceridaemia until levels controlled
SA community gym access: Planet Fitness, Virgin Active, and Gym Company have branches across Gauteng, Western Cape, and KwaZulu-Natal with affordable membership tiers. Many community recreation centres also offer weight rooms at lower cost. Government health clinics sometimes have chronic disease exercise programmes.

Key Nutrients to Monitor and Supplement

Nutrient Why It Matters in Lipodystrophy SA Sources / Options
Omega-3 (EPA + DHA) Lowers triglycerides; anti-inflammatory; reduces cardiovascular risk Pilchards, sardines, mackerel daily; supplement 2–4 g EPA+DHA/day if TGs >5 mmol/L
Vitamin D3 HIV infection and some ARVs impair vitamin D metabolism; deficiency worsens insulin resistance 1 000–2 000 IU/day; check serum 25-OH-D at annual bloods
Magnesium Low in insulin-resistant states; required for glucose metabolism and cardiac health Magnesium glycinate 200–300 mg/day; dark leafy vegetables, pumpkin seeds
Psyllium husk / soluble fibre Lowers LDL and triglycerides; improves glucose control Metamucil or generic psyllium at Dis-Chem; add to water or maas
Coenzyme Q10 Some NRTIs deplete mitochondrial CoQ10; may assist with fatigue 100–200 mg/day; Solgar/Natroceutics brands available SA

Monitoring: Annual Metabolic Checks for Lipodystrophy

Test Why Target
Fasting triglycerides Pancreatitis risk; diet response tracking <1.7 mmol/L; urgent review if >10 mmol/L
Fasting glucose / HbA1c Insulin resistance / diabetes monitoring Fasting glucose <6.1 mmol/L; HbA1c <7% if diabetic
Liver function tests (ALT/AST) NAFLD/MASLD monitoring Within normal range; rising ALT signals worsening fatty liver
Fasting lipid profile (TC, LDL, HDL, TG) Cardiovascular risk management LDL <2.5 mmol/L (or <1.8 in high-risk); HDL >1.0 mmol/L (men), >1.2 (women)
Blood pressure Visceral adiposity and insulin resistance drive hypertension <130/80 mmHg
Waist circumference Tracks visceral fat response to diet and exercise <94 cm men; <80 cm women (IDF criteria)

SA-Specific Resources

Managing lipodystrophy — HIV-associated or genetic?
A dietitian with experience in HIV or metabolic disorders can create a personalised plan for your triglyceride, glucose, and body composition goals. This article is educational only.
Find an SA Dietitian Near You →

Key Takeaways